In this study, we utilize a unique cohort to investigate how the levels of CD163+ immune cells change during tumor progression (from PT to LNM and DM) and determine the clinical relevance of CD163+ immune cells with regards to associations with clinicopathological factors and disease outcomes in MBC. This evidence concerns the gene CD163 and neoplasm.